Hypothyroidism and hyperthyroidism are associated with gain and loss of body weight, respectively. This Review discusses the epidemiological evidence for weight changes in thyroid dysfunction, the role of thyroid hormone in weight regulation, the effect of treatment and the implications for population health.
Parkinson’s disease (PD) is an age-related, progressive neurodegenerative disorder. The hallmark of PD pathogenesis is the Lewy bodies (LBs) that accumulate in neurons in the substantia nigra region of the brain, damaging these neurons and leading to the motor symptoms of the disease. α-synuclein (α-syn), a misfolded protein, aggregates and forms fibrils, which leads to the formation of LBs. The exact molecular mechanism behind this aggregation process is yet to be uncovered. With an increasing number of elderly patients suffering from Parkinson’s and other neurodegenerative diseases worldwide, it is important to understand the aggregation process, find potential therapeutic targets to mitigate or inhibit the aggregation, and slow down the disease progression.
Liquid-liquid phase separation (LLPS), a process where a uniform mixture spontaneously divides into two liquid phases with differing component concentrations, is often considered the reason behind α-syn aggregation. Even though LLPS of α-syn was previously reported, the question remains: are they involved in catalyzing the early stage of aggregation? Ubiquilin-2 (UBQLN2) protein, mainly involved in maintaining protein homeostasis, also undergoes LLPS under certain physiological conditions. Interestingly, it is known to be associated with several neurodegenerative diseases.
Are liquid droplets formed by UBQLN2 catalyzing the α-syn protein aggregation? A team of researchers decided to unravel the involvement of UBQLN2 in α-syn aggregation and fibril formation. “By uncovering the mechanisms that trigger the aggregation process, we hope to find new ways to prevent it and ultimately contribute to the development of disease-modifying treatments,” mentioned the senior author of the study. The study was published in The EMBO Journal.
Scientists found that nanopores’ electrical charges control how ions flow and when pores temporarily shut down. The discovery could allow engineers to design nanopores that “learn” like synapses for next-generation computing.
Pore-forming proteins appear across many forms of life. In humans, they help protect the body by supporting immune defenses. In bacteria, they often function as toxins that create openings in cell membranes. These natural pores regulate the movement of ions and molecules, and their precise control over molecular transport has made them valuable in biotechnology, including DNA sequencing and molecular sensing.
Unpredictable Behavior in Ion Flow.
Researchers in China report that global incidence rates of psoriasis rose slightly from 1990 to 2021 and are projected to continue rising for both men and women through 2050.
Psoriasis is a chronic inflammatory skin disease that continues to impose a growing global burden. Understanding the rate of increase is critical for informing public health strategies, improving health care access, and supporting early diagnosis worldwide.
In the study, “Global Psoriasis Burden and Forecasts to 2050,” published as a Research Letter in JAMA Dermatology, researchers used a time-series forecasting analysis to project global psoriasis incidence through 2050 and to address age, sex, and regional differences in burden.
Researchers have found a way to control protein levels inside different tissues of a whole, living animal for the first time. The method lets scientists dial protein levels up or down with great precision during the animal’s entire life, a technological advance which can help them study the molecular underpinnings of aging and disease.
Scientists at the Center for Genomic Regulation in Barcelona and the University of Cambridge successfully tested the technique by controlling how much protein was present in the intestines and neurons of the nematode worm Caenorhabditis elegans. Their findings are described in the journal Nature Communications.
This Commentary by Md Saidur Rahman, Kyeong A. So & Jae-Wook Jeong discusses Sylvia C. Hewitt et al.: https://doi.org/10.1172/JCI193212
1Department of Obstetrics, Gynecology & Women’s Health, University of Missouri School of Medicine, Columbia, Missouri, USA.
2Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul, Republic of Korea.
Address correspondence to: Jae-Wook Jeong, 1,030 Hitt Street, NextGen Precision Health Building, Columbia, Missouri 65,211, USA. Phone: 573.884.1882; Email: [email protected].
Gene Therapy And A New Era Of Neuroscience — Dr. Norman Putzki, MD — SVP, Global Clinical Development Head, and U.S. Development Site Head, Novartis.
Dr. Norman Putzki, MD is Senior Vice President, Global Clinical Development Head, and U.S. Development Site Head at Novartis (https://www.novartis.com/) where he oversees global teams working on next-generation gene therapies, RNA-based medicines, targeted biologics, and innovative small molecules.
Dr. Putzki most recently served as Global Head of Development for Neuroscience and Gene Therapy at Novartis, where he oversaw one of the world’s most ambitious pipelines aimed at transforming the lives of patients with neurological, neuromuscular, and rare genetic diseases.
A physician–scientist by training, with an MD from University of Duisburg Essen, Dr. Putzki has built a career at the intersection of clinical medicine, translational research, and large-scale drug development.
Before joining Novartis, Dr. Putzki led programs across multiple therapeutic areas at Biogen Idec and has played key roles in advancing clinical treatments for conditions long considered intractable including MS and Parkison’s disease.
Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world’s first synthetic eukaryotic genome in a Nature Biotechnology paper. Their insights could accelerate development of the next generation of engineered organisms, from climate-resilient crops to custom-built cell factories.
“We’ve assembled a comprehensive overview of the literature on how to build a lifeform where we review what went right—but also what went wrong,” says Dr. Paige Erpf, lead author of the paper and postdoctoral researcher at Macquarie University’s School of Natural Sciences and the Australian Research Council (ARC) Center of Excellence in Synthetic Biology.
The Synthetic Yeast Genome Project (Sc2.0) involved a large, evolving global consortium of 200-plus researchers from more than ten institutions, who jointly set out to redesign and chemically synthesize all 16 chromosomes of baker’s yeast from scratch. Macquarie University contributed to the synthesis of two of these chromosomes, comprising around 12% of the project overall.
Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of reach for drug development. The main obstacle was the limited understanding of how these compounds are produced by their microbial hosts.
A research team led by Tobias Gulder, department head at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), has now deciphered the biosynthetic pathway of the biphenomycins, establishing the foundation for their pharmaceutical advancement. The team published its findings in the journal Angewandte Chemie International Edition.
Researchers have developed a precision magnetometer based on a special material that changes optical properties in response to a magnetic field. The device, which is integrated onto a chip, could benefit space missions, navigation and biomedical applications.
High-precision magnetometers are used to measure the strength and direction of magnetic fields for various applications. However, many of today’s magnetometers must operate at extremely low temperatures—close to 0 kelvin—or require relatively large and heavy apparatus, which significantly restricts their practicality.
“Our device operates at room temperature and can be fully integrated onto a chip,” said Paolo Pintus from the University of California, Santa Barbara (UCSB) and the University of Cagliari, Italy, co-principal investigator for the study. “The light weight and low power consumption of this magnetometer make it ideal for use on small satellites, where it could enable studies of the magnetic areas around planets or aid in characterizing foreign metallic objects in space.”